Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous chimeric antigen receptor T cell therapy - Shanghai Keqi Pharmaceutical Technology

Next Previous
Drug Profile

Autologous chimeric antigen receptor T cell therapy - Shanghai Keqi Pharmaceutical Technology

Alternative Names: Autologous CART-TM4SF1 cells - Shanghai Keqi Pharmaceutical Technology; Autologous PTA chimeric antigen receptor T cells - Shanghai Keqi Pharmaceutical Technology

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
  • 31 Jul 2020 Preclinical trials in Solid tumours in China (Parenteral) before July 2020 (ChiCTR2000033564)
  • 31 Jul 2020 Shanghai Keqi Pharmaceutical Technology plans a phase 0 trial for Solid tumours (Recurrent, Second-line therapy or greater, Late-stage disease) in China (ChiCTR2000033564)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top